EW Stock Recent News

EW's Q2 earnings report is likely to benefit from soaring TMTT sales, with the segment expected to jump over 57% year over year.

Besides Wall Street's top-and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

EW gains traction with surgical tech and TAVR growth, but macro pressures and FX headwinds weigh on margins.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2025 after the market closes on Thursday July 24, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards Life.

RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.

Vancouver, British Columbia--(Newsfile Corp. - July 8, 2025) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") is pleased to provide this further corporate update. In the Company's news release of July 2nd 2025 the Company announced a return of capital of approximately $3 million Canadian, subject to receipt of shareholder approval.

Vancouver, British Columbia--(Newsfile Corp. - July 2, 2025) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") announces that the Board of directors has approved, subject to shareholder approval, distribution of capital to the shareholders. The distribution is intended to be structured as a return of capital to the Company's shareholders as of a record date to be determined in the near future.

Edwards Lifesciences is a high-quality, dominant player in structural heart medical devices, with a solid growth history and strong cash generation. The TMTT segment is now the main growth engine, showing rapid expansion, while TAVR growth has plateaued but remains stable. Strategic acquisitions and robust R&D investment position EW for continued innovation and long-term revenue growth above S&P 500 averages.

EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.

PARIS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outco.